Small Molecules

21 Feb 2018 Xenon Pharmaceuticals Advances Second Proprietary Epilepsy Product into the Clinic with Initiation of XEN901 Phase 1 Clinical Trial
20 Feb 2018 Vical Initiates Phase 2 Trial of VL-2397 Antifungal for Invasive Aspergillosis
20 Feb 2018 H3 Biomedicine Preclinical Proof-of-Concept Data on First-in-Class Spliceosome-Modulator Therapy for Genomically Identified Patients with Hematological Cancers Published in Nature Medicine
20 Feb 2018 Sofpironium Bromide Demonstrates Promising Potential as a Safe and Effective First-Line Treatment for Primary Axillary Hyperhidrosis (Excessive Underarm Sweating)
20 Feb 2018 Kancera AB (publ) Reports Positive Results from a Phase I Study in Healthy Subjects With its Lead Immunoregulating Drug Candidate KAND567
20 Feb 2018 Athenex Announces Phase II Clinical Study Results for KX2-391 Ointment for the Treatment of Actinic Keratosis in the American Academy of Dermatology Meeting
20 Feb 2018 FDA Approves Osmotica Pharmaceutical’s Once-Daily OSMOLEX ER™ (amantadine) extended-release tablets for the treatment of Parkinson’s Disease and Drug-Induced Extrapyramidal Reactions in Adults
18 Feb 2018 OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behçet’s Disease with Oral Ulcers
18 Feb 2018 PharmaMar Has Published the Results of Its Antibody Conjugate Active in Breast, Ovarian and Gastric Cancers that Express HER2
18 Feb 2018 AbbVie Announces New Phase 2 Data for Upadacitinib Showing Clinical and Endoscopic Outcomes in Crohn's Disease at 52 Weeks
18 Feb 2018 AbbVie Presents New Late-Breaking Phase 2b Data on Upadacitinib in Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting
16 Feb 2018 OTEZLA® (Apremilast) Phase II Data Showed Clinically Meaningful Improvements in Patients with Active Ulcerative Colitis
15 Feb 2018 FDA Accepts New Drug Application and Grants Priority Review for Ivosidenib in Relapsed or Refractory AML with an IDH1 Mutation
15 Feb 2018 ERLEADA™ (apalutamide), a Next-Generation Androgen Receptor Inhibitor, Granted U.S. FDA Approval for the Treatment of Patients with Non-Metastatic Castration-Resistant Prostate Cancer
15 Feb 2018 AMAG Pharmaceuticals Announces FDA Approval of Makena® (hydroxyprogesterone caproate injection) Subcutaneous Auto-Injector to Reduce the Risk of Preterm Birth in Certain At-Risk Women
15 Feb 2018 Daiichi Sankyo Submits Marketing Application for Mirogabalin in Japan
14 Feb 2018 Galmed Announces ARRIVE Study Data
14 Feb 2018 Pfizer Receives Breakthrough Therapy Designation from FDA for PF-04965842, an oral JAK1 Inhibitor, for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis
14 Feb 2018 Exelixis Announces Results from a Phase 2 Investigator-Sponsored Trial of Cabozantinib in the First-Line Treatment of Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma
14 Feb 2018 Sensorion Presents New SENS-401 Data at ARO 2018 MidWinter Meeting
14 Feb 2018 Athenex Announces Early Completion of Patients Enrollment for Two Phase III Clinical Studies of KX2-391 Ointment for Actinic Keratosis
14 Feb 2018 MyoKardia Begins Patient Dosing in Phase 1b Clinical Study of MYK-491 in Dilated Cardiomyopathy Patients
14 Feb 2018 Vertex Announces Treatment with the NaV1.8 Inhibitor VX-150 Showed Significant Relief of Acute Pain in Phase 2 Study
14 Feb 2018 Tetraphase Announces Top-Line Results from IGNITE3 Phase 3 Clinical Trial of Eravacycline in Complicated Urinary Tract Infections (cUTI)
14 Feb 2018 Ortho Dermatologics Announces U.S. FDA Filing Acceptance For JEMDEL™ Plaque Psoriasis Treatment

La Merie Biologics

FREE Weekly News Bulletin

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing